

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

CYTOKLONAL PHARMACEUTICS

---

(Name of Issuer)

Common Stock

---

(Title of Class of Securities)

23282G105

---

(CUSIP Number)

Paul F. Byrne c/o Janssen-Meyers Associates, L.P. 17 State Street,  
NY, NY 10004  
(212) 742-4200

---

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and  
Communications)

11/2/95

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box \_\_\_\_.

Check the following box if a fee is being paid with the statement \_\_\_\_\_. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (Sec Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Name of Reporting Person

Janssen-Meyers Associates, L.P.

---

S.S. or I.R.S. Identification No. of Above Person

---

2. Check the Appropriate Box if a Member of a Group  
(See Instructions before filling out)

a. \_\_\_\_\_ b. ☒ X

3. SEC USE ONLY

---

4. Source of Funds (See instructions before filling out).

---

5. Check Box if Disclosure of Legal Proceedings is  
Required Pursuant to Items  
2(d) or 2(e).

---

6. Citizenship or Place of Organization

USA NY Limited Partnership

---

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON  
(Questions 7 - 10)

7. Sole Voting Power  
1,689,500 shares Common Stock

---

8. Shared Voting Power

---

9. Sole Dispositive Power

1,689,500 shares Common Stock

---

10. Shared Dispositive Power

---

11. Aggregate Amount Beneficially Owned by Each  
Reporting Person

1,689,500 shares Common Stock

---

12. Check Box if the Aggregate Amount in Row (11)  
Excludes Certain Shares  
(See instructions before filling out)

NA

---

13. Percent of Class Represented by Amount in Row (11)

22.8%

---

14. Type of Reporting Person (See instructions  
before filling out)

BD/PN

---